Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial.

Abstract:

:The trial CICL670AUS04 was a single-arm, open-label study of the cardiac efficacy of 18 months of deferasirox monotherapy [1]. Cardiac response in this study was related to the degree of liver siderosis. Patients with mild to moderate liver siderosis improved their cardiac T2* while more severely siderotic patients did not, regardless of initial cardiac iron burden. In this letter, we report 2-year data in those patients who completed a 6-month extension phase (N 5 10). Cardiac and liver iron improved steadily during the 24-month period, with final cardiac T2* and LIC improving 37% and 27%, respectively, in this cohort. Serum ferritin and LVEF were not statistically different at anytime-point. When the extension phase (18-24 months) was considered in isolation, serum ferritin, liver iron concentration, and left ventricular ejection fraction were nearly identical to 18 month results. Despite this, cardiac T2* continued to trend higher, increasing 12.7% from 9.5 ms to 10.7 ms (P 5 0.06). Thus defersirox continued to demonstrate cardiac efficacy in patients with mild to moderate hepatic siderosis throughout 2 years of therapy.

journal_name

Am J Hematol

authors

Wood JC,Glynos T,Thompson A,Giardina P,Harmatz P,Kang BP,Paley C,Coates TD

doi

10.1002/ajh.21830

subject

Has Abstract

pub_date

2010-10-01 00:00:00

pages

818-9

issue

10

eissn

0361-8609

issn

1096-8652

journal_volume

85

pub_type

临床试验,信件
  • Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers.

    abstract::Granulocyte-macrophage colony-stimulating factor (GM-CSF) (250 microg/m2) was administered subcutaneously to 7 normal volunteers for up to 14 days to study its effects on neutrophil kinetics and function. With treatment, blood neutrophil counts rose gradually to peak at 3 1/2 times baseline by day 14. At day 5 marrow ...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/(sici)1096-8652(199801)57:1<7::aid-ajh2>3.

    authors: Dale DC,Liles WC,Llewellyn C,Price TH

    更新日期:1998-01-01 00:00:00

  • Platelet glycoprotein Ia 807C/T (Phe224) and 873G/A (Thr246) dimorphisms in Turkey.

    abstract::At sites of vascular injury, the platelet collagen receptor Glycoprotein Ia/IIa (GPIa/IIa) acts as an important mediator of platelet adhesion to fibrillar collagens. Two silent polymorphisms (807C/T and 873G/A) within the glycoprotein Ia gene have been implicated in increased risk of developing thrombosis and myocardi...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.10029

    authors: Komurcu E,Erginel-Unaltuna N

    更新日期:2002-01-01 00:00:00

  • Serum from outdated human platelet concentrates: an alternative supplement for tissue (fibroblast) culture media.

    abstract::Fetal calf serum (FCS) is used as a component of the media for cells grown in culture. However, the high cost of FCS has stimulated a search for a possible alternative. Approximately 10% of human platelet concentrates prepared for clinical transfusions are outdated. Sera prepared from platelet concentrates were compar...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830170104

    authors: Schwartz KA,Lu G,Trosko JE,Chang CC

    更新日期:1984-07-01 00:00:00

  • Predictive value of enzyme-linked immunoassay platelet crossmatching for transfusion of platelet concentrates to alloimmunized recipients.

    abstract::Some evidence has shown that platelet crossmatching is useful in multitransfused patients with hypoplastic bone marrows who are refractory to platelet therapy through alloimmunization. Several immunoglobulin binding assays other than enzyme-linked immunospecific assay (ELISA) have been studied previously. We performed...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830240407

    authors: Brubaker DB,Duke JC,Romine M

    更新日期:1987-04-01 00:00:00

  • Post-transfusion purpura associated with alloimmunization against the platelet-specific antigen, Baka.

    abstract::Post-transfusion purpura (PTP) with severe thrombocytopenia occurred eight days after transfusion in a 28-year-old woman and responded to treatment with prednisone and plasma exchange. In contrast to nearly all previously studied cases of PTP, the patient's platelets were PlA1-positive and anti-PlA1 antibody could not...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830210110

    authors: Keimowitz RM,Collins J,Davis K,Aster RH

    更新日期:1986-01-01 00:00:00

  • Myelodysplastic transformation of polycythemia vera: case report and review of the literature.

    abstract::We report a case of refractory anemia with excess blasts (RAEB) developing in a 67-year old man with a history of polycythemia vera; results of cytogenetic and immunophenotyping studies are described. In this report the clinical, cytogenetic and hematologic features of myelodysplasia complicating polycythemia vera are...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.2830370110

    authors: Shamdas GJ,Spier CM,List AF

    更新日期:1991-05-01 00:00:00

  • Membrane cation and anion transport activities in erythrocytes of hereditary spherocytosis: effects of different membrane protein defects.

    abstract::Hereditary spherocytosis (HS) is due to different membrane protein defects (i.e., deficiency of spectrin and ankyrin, band 3, or band 4.2). In order to gain new insight into the relationships between band 3 function and proteins associated with the cytoskeleton, we studied erythrocyte anion transport activity in HS ch...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/(sici)1096-8652(199707)55:3<121::aid-ajh1>

    authors: De Franceschi L,Olivieri O,Miraglia del Giudice E,Perrotta S,Sabato V,Corrocher R,Iolascon A

    更新日期:1997-07-01 00:00:00

  • Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.

    abstract::The introduction of Imatinib (IM) has significantly altered the treatment for CML, although only limited follow-up results are available. As failure of Interferon-alpha had been associated with poor prognosis and results of IM-treatment in this patient group may allow earlier estimation of long-term benefits for early...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.21055

    authors: Hess G,Meyer RG,Schuch B,Bechthold K,El-Kholy I,Huber C

    更新日期:2008-03-01 00:00:00

  • Prenatal and molecular diagnosis of hemophilia B.

    abstract::Prenatal diagnosis was carried out on a woman who had previously given birth to a son with a spontaneous mutation of C-->T transition at nt 31133 of the factor IX (F.IX) gene. The diagnosis was performed on chorionic villi sampling by the method of amplification-created restriction site (ACRS). It revealed a female fe...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/(SICI)1096-8652(199608)52:4<243::AID-AJH1>

    authors: Young JH,Wang JC,Gau JP,Hu HT

    更新日期:1996-08-01 00:00:00

  • Application of a monoclonal antibody specific for the delta chain of hemoglobin A2 in the diagnosis of beta thalassemia.

    abstract::We have developed a murine monoclonal antibody (mAb) specific for the delta chain of hemoglobin (Hb) A2 that does not cross-react with alpha, beta, or gamma chains. The mAb reacted with Hb P-Nilotic (beta delta hybrid), but not with Hb Lepore-Boston (delta beta hybrid), indicating an epitope consisting of positions 11...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830380311

    authors: Shyamala M,Kiefer CR,Moscoso H,Garver FA

    更新日期:1991-11-01 00:00:00

  • Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.

    abstract::Duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-δ and -γ, was evaluated in a Phase 1 study in advanced hematologic malignancies, which included expansion cohorts in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and treatment-naïve (TN) CLL...

    journal_title:American journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ajh.25243

    authors: O'Brien S,Patel M,Kahl BS,Horwitz SM,Foss FM,Porcu P,Jones J,Burger J,Jain N,Allen K,Faia K,Douglas M,Stern HM,Sweeney J,Kelly P,Kelly V,Flinn I

    更新日期:2018-11-01 00:00:00

  • Immunological abnormalities in splenic marginal zone cell lymphoma.

    abstract::The clinical features of patients with splenic marginal zone cell lymphoma (SMZCL) have rarely been reported. In the present study, immunological abnormalities, particularly hematological abnormalities, observed in SMZCL were described. Autoimmune hemolytic anemia, immune thrombocytopenia, and appearance of lupus anti...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1096-8652(199711)56:3<173::aid-ajh7>

    authors: Murakami H,Irisawa H,Saitoh T,Matsushima T,Tamura J,Sawamura M,Karasawa M,Hosomura Y,Kojima M

    更新日期:1997-11-01 00:00:00

  • Factor VIII and IX gene polymorphisms and carrier analysis in Indian population.

    abstract::The efficacy of the three common intra- and extragenic polymorphic sites of the factor VIII and IX genes has been examined in the Indian population, with an aim to develop a strategy that would be accurate and informative, yet economical. The approach for hemophilia A carrier detection includes tests for BclI, XbaI, a...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/(sici)1096-8652(199704)54:4<271::aid-ajh2>

    authors: Shetty S,Ghosh K,Pathare A,Colah R,Badakare S,Mohanty D

    更新日期:1997-04-01 00:00:00

  • Bone marrow failure and myelofibrosis in a case of PVP storage disease.

    abstract::"PVP storage disease" is a disorder occurring in patients who have received high molecular weight polyvinylpyrrolidone (PVP), which cannot be excreted from the body. These large polymers deposit in the histiocytes and cause proliferation and infiltration of histiocytes in the reticuloendothelial system. There was usua...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/(sici)1096-8652(199801)57:1<68::aid-ajh12>

    authors: Dunn P,Kuo T,Shih LY,Wang PN,Sun CF,Chang MJ

    更新日期:1998-01-01 00:00:00

  • Laparoscopic splenectomies for idiopathic thrombocytopenic purpura: experience of sixty cases.

    abstract::We performed a laparoscopic splenectomy (LS) in 60 patients (age 9-83, 45 females) with idiopathic thrombocytopenic purpura (ITP) who did not achieve sustained remission on steroid therapy. Using a modified procedure, the mean duration of LS was 78 min (range 25-240 min) and surgery was associated with only 5% major a...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/(sici)1096-8652(200001)63:1<7::aid-ajh2>3.

    authors: Szold A,Schwartz J,Abu-Abeid S,Bulvik S,Eldor A

    更新日期:2000-01-01 00:00:00

  • Host-tumor interactions: basis for the anemia in rats bearing the hepatoma 7777.

    abstract::A significant anemia develops in Buffalo rats bearing the Morris hepatoma 7777. By indiceal measurements the red blood cells (RBCs) appear to be microcytic and hypochromic. Ferrokinetic studies demonstrate a decreased uptake of iron in the bone marrow and an increased incorporation of iron in the spleens of the tumor-...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830070205

    authors: Lamar C Jr,Greene AS,Greene WB

    更新日期:1979-01-01 00:00:00

  • Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

    abstract::This analysis, using data from the bortezomib-melphalan-prednisone (VMP) arm of the Phase III VISTA study, investigated whether increased cumulative bortezomib dose could improve overall survival (OS) in transplant-ineligible patients with previously untreated multiple myeloma. Median cumulative bortezomib dose receiv...

    journal_title:American journal of hematology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/ajh.23933

    authors: Mateos MV,Richardson PG,Dimopoulos MA,Palumbo A,Anderson KC,Shi H,Elliott J,Dow E,van de Velde H,Niculescu L,San Miguel JF

    更新日期:2015-04-01 00:00:00

  • Chylothorax in chronic lymphocytic leukemia patient.

    abstract::Chronic lymphocytic leukemia (CLL) is rarely complicated by chylothorax: we present a 93-year-old woman with CLL who developed recurrent pleural effusions that were ultimately found to be chylous in nature. Despite eight repeated thoracenteses, she continued to experience re-accumulation of fluid, and therefore, video...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.10142

    authors: Doerr CH,Staats BA,Markovic SN

    更新日期:2002-07-01 00:00:00

  • The "Hageman" connection: interrelationships of blood coagulation, fibrino(geno)lysis, kinin generation, and complement activation.

    abstract::The activation pathways for the generation of enzymes involved in blood clotting, clot lysis, complement activation, and kinin generation are briefly reviewed. The interrelationship of the four systems is illustrated by the multiple functions of four key enzymes: Factor XIIa, kallikrein, plasmin, and C1 esterase. The ...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.2830040412

    authors: Murano G

    更新日期:1978-01-01 00:00:00

  • Ultrasound-guided fine needle biopsy of the spleen: high clinical efficacy and low risk in a multicenter Italian study.

    abstract::The aim of this study was to evaluate the clinical efficacy and safety of the ultrasound-guided fine needle biopsy (UG-FNB) of the spleen in a large population of patients. We collected retrospectively the findings concerning the application of UG-FNB of the spleen from eight Italian clinical centers that utilized thi...

    journal_title:American journal of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/ajh.1085

    authors: Civardi G,Vallisa D,Bertè R,Giorgio A,Filice C,Caremani M,Caturelli E,Pompili M,De Sio I,Buscarini E,Cavanna L

    更新日期:2001-06-01 00:00:00

  • Report of a factor VIII inhibitor in a patient with autoimmune lymphoproliferative syndrome.

    abstract::The occurrence of factor VIII inhibitors in non-hemophilic patients is a rare event with a potentially lethal outcome. Despite its infrequent occurrence, the association of this inhibitor with multiple autoimmune diseases is well recognized. We report the case of a patient with the recently described autoimmune lympho...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/1096-8652(200007)64:3<214::aid-ajh14>3.0.c

    authors: Fang BS,Sneller MC,Straus SE,Frenkel L,Dale JK,Rick ME

    更新日期:2000-07-01 00:00:00

  • Acute myeloid leukemia: 2014 update on risk-stratification and management.

    abstract:OVERVIEW:Evidence suggests that even patients aged 70 or above benefit from specific AML therapy. The fundamental decision in AML then becomes whether to recommend standard or investigational treatment. This decision must rest on the likely outcome of standard treatment. Hence we review factors that predict treatment r...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.23834

    authors: Estey EH

    更新日期:2014-11-01 00:00:00

  • Danazol for paroxysmal nocturnal hemoglobinuria.

    abstract::Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal stem-cell disorder in which blood cells lack complement inhibiting membrane proteins, and become susceptible to complement-mediated injury, leading to chronic intravascular hemolysis and pancytopenia. Glucocorticoids have been a mainstay of therapy. For patien...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1096-8652(199702)54:2<149::aid-ajh9>

    authors: Harrington WJ Sr,Kolodny L,Horstman LL,Jy W,Ahn YS

    更新日期:1997-02-01 00:00:00

  • The hope and reality of long-acting hemophilia products.

    abstract::Recombinant DNA technology and protein engineering are creating hope that we can address ongoing challenges in hemophilia care such as reducing the costs of therapy, increasing the availability to the developing world, and improving the functional properties of these proteins. Technological advances to improve the hal...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.23146

    authors: Pipe SW

    更新日期:2012-05-01 00:00:00

  • Platelet interaction with bacteria. VI. contrasting the role of fibrinogen and fibronectin.

    abstract::The roles of fibrinogen and fibronectin were contasted in the responses of human platelets to Staphylococcus aureus and collagen. Congenital afibrinogenemic (CA) platelets and washed normal platelets had delayed aggregation due to a prolonged latent phase in response to contact with the bacteria when fibrinogen was ab...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830090106

    authors: Clawson CC,White JG,Herzberg MC

    更新日期:1980-01-01 00:00:00

  • High-dose methylprednisolone is an alternative treatment for adults with autoimmune thrombocytopenic purpura refractory to intravenous immunoglobulins and oral corticosteroids.

    abstract::Eight patients with severe chronic autoimmune thrombocytopenic purpura (AITP) refractory to high-dose intravenous immunoglobulin (IVIgG) and/or oral prednisone were treated with one to three infusions of high-dose methylprednisolone (HDMP) (15 mg/kg/day). The mean platelet count before treatment was 12 +/- 10 x 10(9)/...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830480416

    authors: Godeau B,Zini JM,Schaeffer A,Bierling P

    更新日期:1995-04-01 00:00:00

  • Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies.

    abstract::Complete remission can be achieved in 60-80% of adults with diffuse aggressive non-Hodgkin's lymphoma. However, 20-40% of them will subsequently relapse. Nevertheless, formal follow-up guidelines for recurrence detection have never been advocated. We analyzed the pattern of relapse in 30 patients with intermediate- an...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.10017

    authors: Elis A,Blickstein D,Klein O,Eliav-Ronen R,Manor Y,Lishner M

    更新日期:2002-01-01 00:00:00

  • Cancer immunotherapy targeting Sp17: when should the laboratory findings be translated to the clinics?

    abstract::Despite advances in chemotherapeutic agents, the prognosis for some cancers remains extremely poor, suggesting the need for other treatment modalities. Immunotherapy appears an ideal approach because the mechanisms of tumor cell killing induced by tumor vaccines are different from those from chemotherapy. Various inve...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.20415

    authors: Dadabayev AR,Wang Z,Zhang Y,Zhang J,Robinson WR,Lim SH

    更新日期:2005-09-01 00:00:00

  • Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.

    abstract:DISEASE OVERVIEW:Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extracutaneous organs. DIAGNOSIS:The major criterion is presence of multifocal clusters of morphologically abnormal MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase...

    journal_title:American journal of hematology

    pub_type: 杂志文章,评审

    doi:10.1002/ajh.23459

    authors: Pardanani A

    更新日期:2013-07-01 00:00:00

  • Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.

    abstract::Circulating thrombomodulin is a novel endothelial cell marker, which may reflect the endothelial injury. Plasma levels of thrombomodulin were quantitated by an enzyme-linked immunosorbent assay (ELISA) in patients with hematological malignancies, liver disease, diabetes mellitus, collagen disease, thrombotic disease, ...

    journal_title:American journal of hematology

    pub_type: 杂志文章

    doi:10.1002/ajh.2830410107

    authors: Takahashi H,Ito S,Hanano M,Wada K,Niwano H,Seki Y,Shibata A

    更新日期:1992-09-01 00:00:00